glp-1 news 2025 october 9 Looming drug patent expirations draw generics firms ISPOR 2025: Exploring reasons for
Description
Novo Nordisk and Eli Lilly become latest drug companies to bend knee to Trumps most-favored nation pricing plan
That might show up as a great result on the scale, but it leaves people metabolically weaker, not stronger
The growing prevalence of metabolic disease, CKD, and ASCVD have prompted investigation into the role of GLP-1R agonists in mitigating cardiovascular and metabolic risks, particularly within the framework of Cardiovascular-Kidney-Metabolic (CKM) Syndrome, irrespective of diabetic status
I am always open to questions, comments, and suggestions.Please note this account is not affiliated with Mounjaro
GLP-1 medications drive costs
David Shafer explains why volume loss appears, what helps, and when fillers may work.
